We advised the underwriters in connection with the equity offering

Davis Polk advised the underwriters in connection with a public offering of 6,666,666 shares of common stock of Revolution Medicines, Inc. at $45.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 869,595 additional shares), for total gross proceeds of $300 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”

 

Based in Redwood City, California, Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers.

 

The Davis Polk corporate team included partner Alan F. Denenberg and associate Daniel Reichert. The intellectual property and technology transactions team included partner David R. Bauer and associate Daniel P. Kearney. The tax team included partner Michael Farber and associate Tyler Scheiner. Counsel Marcie A. Goldstein provided FINRA advice. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post